AI Insight
The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets for treating narcolepsy type 1 in adults. This medication represents the first drug approved to address the complete spectrum of narcolepsy type 1 symptoms and is the first to directly target the underlying cause of the disease—the loss of orexin signaling in the brain.
Why it matters
This approval provides a new treatment approach for narcolepsy type 1 patients by addressing the root neurological cause rather than just managing individual symptoms. The drug could significantly improve quality of life for adults suffering from this chronic sleep disorder by offering more comprehensive symptom control.
Understand the Science
The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) tablets to treat narcolepsy type 1 in adults. Orzeyful marks the first medication approved for the full range of symptoms associated with narcolepsy type 1 and is the first approved drug to directly target the loss of orexin signaling that causes the disease.
Source: FDA approves first drug for full range of narcolepsy symptoms